Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Magnitude of unreported kala-azar cases in a highly endemic district of Bihar, India: A positive impact of Indian elimination programme.

Journal of vector borne diseases·2020

Same author

Studying land use dynamics using decadal satellite images and Dyna-CLUE model in the Mahanadi River basin, India.

Environmental monitoring and assessment·2020

Same author

Developing quantifiable approaches for delineating suitable options for irrigating fallow areas during dry season-a case study from Eastern India.

Environmental monitoring and assessment·2020

Same author

Search for dark matter produced in association with heavy-flavor quark pairs in proton-proton collisions at <math> </math>.

The European physical journal. C, Particles and fields·2020

Same author

A Clinical Study of Peripheral Arterial Disease in Diabetes Mellitus with Reference to Ankle Brachial Pressure Index and Doppler sonography.

The Journal of the Association of Physicians of India·2020

Same author

Extraction and validation of a new set of CMS pythia8 tunes from underlying-event measurements.

The European physical journal. C, Particles and fields·2020

Search research articles

Related Experiment Video

Updated: May 13, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Exploring novel KDR inhibitors based on pharmaco-informatics methodology.

R K Kar¹, P Suryadevara, B R Sahoo

¹Biomedical Informatics Centre, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.

SAR and QSAR in Environmental Research

|February 27, 2013

Summary

Researchers identified key molecular features for designing potent Kinase-insert domain-containing receptor (KDR) inhibitors using computational methods. This study highlights urea derivatives and active site hydrophobicity for improved KDR drug development.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: May 13, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

Medicinal Chemistry
Computational Drug Discovery
Pharmacology

Background:

Kinase-insert domain-containing receptor (KDR) is a key mediator of Vascular Endothelial Growth Factor (VEGF) signaling in endothelial cells.
Inhibiting KDR offers therapeutic potential for various diseases.
Understanding KDR-inhibitor interactions is crucial for drug development.

Purpose of the Study:

To explore novel KDR inhibitors using in silico methodologies.
To identify critical structural requirements for potent KDR inhibitors.
To provide insights for designing effective KDR-targeting drugs.

Main Methods:

Employed three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis with atom-based pharmacophore mapping on 85 molecules.
Utilized virtual screening to identify potential KDR inhibitors.
Validated the pharmacophore model for robustness and predictive power.

Main Results:

Developed a statistically validated 3D-QSAR model (Q(2)=0.865, r(2)=0.789, external r(2)=0.925) for designing active KDR inhibitors.
Identified urea backbone structures as promising scaffolds for KDR inhibitors.
Highlighted the significance of active site hydrophobicity, previously overlooked, for KDR inhibitor design.

Conclusions:

The study quantifies essential structural features for favorable KDR receptor binding.
Urea derivatives and specific active site interactions are crucial for potent KDR inhibitors.
Findings offer valuable structural guidance for medicinal chemists in developing novel KDR-targeting therapeutics.